Clinicopathological and Prognostic values of Gankyrin, Snail1, and IDH1 Expression in Renal Cell Carcinoma Patients

IF 0.4 Q4 ONCOLOGY
R. Kaf, O. Harb, Magid M. Ali, N. Salama, T. Baiomy, Marwa I Abdelgawad, L. Abdelaziz.
{"title":"Clinicopathological and Prognostic values of Gankyrin, Snail1, and IDH1 Expression in Renal Cell Carcinoma Patients","authors":"R. Kaf, O. Harb, Magid M. Ali, N. Salama, T. Baiomy, Marwa I Abdelgawad, L. Abdelaziz.","doi":"10.30476/MEJC.2021.86762.1370","DOIUrl":null,"url":null,"abstract":"Background: Gankyrin is an oncoprotein incriminated in cancer growth, invasion, and spread. Snail1 is associated with mesenchymal features acquisition that is related to invasion and metastasis of malignant cells. Isocitrate dehydrogenase 1(IDH1) has been found to be mutated in several cancers, which leads to altered cellular metabolism and tumorgenesis. The present study aimed to assess Gankyrin, Snail1, and IDH1 expression patterns and compare them to clinicopathological and prognostic parameters. \nMethod: In our prospective cohort study, the samples taken from 60 RCC patients were processed, diagnosed, graded, staged, and subjected to immunohistochemistry for Gankyrin, Snail1, and IDH1. The patients were chosen, treated, and followed up from January 2015 to December 2019. Overall, the survival (OS) and progression-free survival (PFS) were assessed. \nResults: High expression levels of Gankyrin were positively associated with high grade (P=0.003), stage (P =0.033), and size of the tumor (P=0.049), in addition to lymph nodes metastasis (P =0.01), distant metastases (P=0.007), higher incidence of tumor progression, unfavorable 5-year progression-free survival, and overall survival rates (P<0.001). High expression levels of Snail1 were positively associated with high grade (P=0.004) and stage (P=0.023) of the tumors, on top of lymph nodes metastasis (P=0.003), distant metastases (P=0.002), higher incidence of tumor progression, poorer five-year progression-free survival, and overall survival rates (P<0.001). High expression levels of IDH1 were negatively associated with low grade (P = 0.002), stage, and size of the tumor and lymph nodes metastasis (P<0.001), distant metastases (P =0.041), lower incidence of tumor progression (P=0.013), better five-year progression-free survival, and overall survival rates (P<0.041). \nConclusion: We indicated the associations between poor RCC pathological parameters, unfavorable patients’ outcome, high Gankyrin, high Snail1, and reduced IDH1 expression.","PeriodicalId":44005,"journal":{"name":"Middle East Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":0.4000,"publicationDate":"2021-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Middle East Journal of Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.30476/MEJC.2021.86762.1370","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Gankyrin is an oncoprotein incriminated in cancer growth, invasion, and spread. Snail1 is associated with mesenchymal features acquisition that is related to invasion and metastasis of malignant cells. Isocitrate dehydrogenase 1(IDH1) has been found to be mutated in several cancers, which leads to altered cellular metabolism and tumorgenesis. The present study aimed to assess Gankyrin, Snail1, and IDH1 expression patterns and compare them to clinicopathological and prognostic parameters. Method: In our prospective cohort study, the samples taken from 60 RCC patients were processed, diagnosed, graded, staged, and subjected to immunohistochemistry for Gankyrin, Snail1, and IDH1. The patients were chosen, treated, and followed up from January 2015 to December 2019. Overall, the survival (OS) and progression-free survival (PFS) were assessed. Results: High expression levels of Gankyrin were positively associated with high grade (P=0.003), stage (P =0.033), and size of the tumor (P=0.049), in addition to lymph nodes metastasis (P =0.01), distant metastases (P=0.007), higher incidence of tumor progression, unfavorable 5-year progression-free survival, and overall survival rates (P<0.001). High expression levels of Snail1 were positively associated with high grade (P=0.004) and stage (P=0.023) of the tumors, on top of lymph nodes metastasis (P=0.003), distant metastases (P=0.002), higher incidence of tumor progression, poorer five-year progression-free survival, and overall survival rates (P<0.001). High expression levels of IDH1 were negatively associated with low grade (P = 0.002), stage, and size of the tumor and lymph nodes metastasis (P<0.001), distant metastases (P =0.041), lower incidence of tumor progression (P=0.013), better five-year progression-free survival, and overall survival rates (P<0.041). Conclusion: We indicated the associations between poor RCC pathological parameters, unfavorable patients’ outcome, high Gankyrin, high Snail1, and reduced IDH1 expression.
Gankyrin、Snail1和IDH1在肾癌患者中的表达及其临床病理和预后价值
背景:甘肽是一种参与肿瘤生长、侵袭和扩散的癌蛋白。Snail1与恶性细胞侵袭和转移相关的间充质特征获得相关。异柠檬酸脱氢酶1(IDH1)已被发现在几种癌症中发生突变,从而导致细胞代谢改变和肿瘤发生。本研究旨在评估Gankyrin、Snail1和IDH1的表达模式,并将它们与临床病理和预后参数进行比较。方法:在我们的前瞻性队列研究中,对60例RCC患者的样本进行处理、诊断、分级、分期,并进行Gankyrin、Snail1和IDH1的免疫组织化学检测。从2015年1月至2019年12月对患者进行选择、治疗和随访。总体而言,评估生存期(OS)和无进展生存期(PFS)。结果:Gankyrin高表达水平与肿瘤的高分级(P=0.003)、分期(P= 0.033)、大小(P=0.049)呈正相关,与淋巴结转移(P= 0.01)、远处转移(P=0.007)、更高的肿瘤进展发生率、不利的5年无进展生存期和总生存率呈正相关(P<0.001)。Snail1的高表达水平与肿瘤的高分级(P=0.004)、分期(P=0.023)、淋巴结转移(P=0.003)、远处转移(P=0.002)、更高的肿瘤进展发生率、更差的5年无进展生存期和总生存率(P<0.001)呈正相关。高表达水平的IDH1与肿瘤的低分级(P= 0.002)、分期、大小、淋巴结转移(P<0.001)、远处转移(P= 0.041)、较低的肿瘤进展发生率(P=0.013)、较好的5年无进展生存期和总生存率(P<0.041)呈负相关。结论:我们提示RCC病理参数差、患者预后不良、高Gankyrin、高Snail1和IDH1表达降低之间存在关联。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.80
自引率
0.00%
发文量
0
审稿时长
12 weeks
期刊介绍: Middle East Journal of Cancer (MEJC) is an international peer-reviewed journal which aims to publish high-quality basic science and clinical research in the field of cancer. This journal will also reflect the current status of research as well as diagnostic and treatment practices in the field of cancer in the Middle East, where cancer is becoming a growing health problem. Lastly, MEJC would like to become a model for regional journals with an international outlook. Accordingly, manuscripts from authors anywhere in the world will be considered for publication. MEJC will be published on a quarterly basis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信